1. Home
  2. 4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy-

Contact Angene

Tel: +852 8191 6999

Email: [email protected]

Brc1cnc(nc1)C
Pyrimidine, 5-bromo-2-methyl-
CCCP1(=O)OP(=O)(CCC)OP(=O)(O1)CCC
1,3,5,2,4,6-Trioxatriphosphorinane, 2,4,6-tripropyl-, 2,4,6-trioxide
CC1(C)OB(OC1(C)C)B1OC(C(O1)(C)C)(C)C
2,2'-Bi-1,3,2-dioxaborolane, 4,4,4',4',5,5,5',5'-octamethyl-
O=C(C=Cc1ccccc1)C=Cc1ccccc1.O=C(C=Cc1ccccc1)C=Cc1ccccc1.O=C(C=Cc1ccccc1)C=Cc1ccccc1.[Pd].[Pd]
Tris(dibenzylideneacetone)dipalladium
C1CCC(CC1)P(C1CCCCC1)C1CCCCC1.Cc1cc(C)c(c(c1)C)N1CCN(C1=[Ru](=Cc1ccccc1)(Cl)Cl)c1c(C)cc(cc1C)C
Ruthenium,[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro(phenylmethylene)(tricyclohexylphosphine)-, (SP-5-41)-

4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy-

COc1cc2c(ncnc2cc1OC)Nc1cccc(c1)Br Request for Quotation
Chemical Name: 4-Quinazolinamine, N-(3-bromophenyl)-6,7-dimethoxy-
CAS Number: 153436-54-5
Product Number: AG007Y3U(AGN-PC-0JK6ZA)
Synonyms:
MDL No:
Molecular Formula: C16H14BrN3O2
Molecular Weight: 360.2053

Identification/Properties

Computed Properties
Molecular Weight:
360.211g/mol
XLogP3:
4
Hydrogen Bond Donor Count:
1
Hydrogen Bond Acceptor Count:
5
Rotatable Bond Count:
4
Exact Mass:
359.027g/mol
Monoisotopic Mass:
359.027g/mol
Topological Polar Surface Area:
56.3A^2
Heavy Atom Count:
22
Formal Charge:
0
Complexity:
360
Isotope Atom Count:
0
Defined Atom Stereocenter Count:
0
Undefined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Covalently-Bonded Unit Count:
1
Compound Is Canonicalized:
Yes

Safety Information

GHS Pictogram:
Signal Word:
Warning
UN#:
-
Hazard Statements:
H302-H315-H319-H332-H335
Precautionary Statements:
P261-P280-P305+P351+P338
Class:
-
Packing Group:
-

NMR Spectrum

Other Analytical Data

Request for Quotation

Customer Feedback

Chemical Structure


PD153035 is a potent and highly selective inhibitor of the epidermal growth factor receptor (EGFR). Its unique structure and mechanism of action make it a valuable tool in chemical synthesis, particularly in the development of targeted therapeutics for various diseases, including cancer. By specifically inhibiting EGFR, PD153035 can help researchers better understand the role of this receptor in signaling pathways and disease progression. This can lead to the discovery of new treatment strategies and the development of novel compounds with improved therapeutic properties. In chemical synthesis, PD153035 can be used to study protein-protein interactions, receptor-ligand binding, and signal transduction pathways, providing valuable insights into molecular mechanisms and potential drug targets. Its versatile applications make PD153035 a valuable asset in the field of chemical biology and drug discovery.